The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Michael Rosen named chief communications officer at Pancreatic Cancer Action Network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Michael Rosen was named chief communications officer at the Pancreatic Cancer Action Network.

One of Rosen’s key roles will be increasing awareness about the organization’s ground breaking research and clinical initiatives like Precision Promise, a revolutionary clinical trial that will dramatically accelerate progress and bring promising therapies to patients faster.

Most recently, Rosen served as executive vice president of marketing and communications for the Mental Health Association of New York City, where he managed all marketing, communications strategies and development.

Between 2013 and 2016, Rosen led strategic communications for Autism Speaks, the world’s largest autism advocacy organization.

Prior to entering the nonprofit sector, Rosen was the executive producer first of The Saturday Early Show and then CBS This Morning Saturday. At ABC News, Rosen was second in charge for the network’s Peabody Award-winning coverage of 9/11, and covered the war in Kosovo on location. Rosen has won three Emmy Awards, two Peabody Awards and four DuPont Awards.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account